DISPERSE2-TIMI 33 evaluated the safety, tolerability, and efficacy of AZD6140 (ticagrelor), an oral reversible ADP receptor antagonist, compared with clopidogrel in patients with non-ST segment elevation acute coronary syndrome. MAIN RESULTS: Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute … Continue reading DISPERSE2-TIMI 33